相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sofosbuvir: A Nucleotide NS5B Inhibitor for the Treatment of Chronic Hepatitis C Infection
Lucia Rose et al.
ANNALS OF PHARMACOTHERAPY (2014)
Vitamin D Deficiency and Liver Cancer: More Than Just an Epidemiological Association?
Massimo Colombo et al.
HEPATOLOGY (2014)
Monitoring and Treatment of Inactive Chronic Hepatitis B: Is It Cost-Effective?
Zobair Younossi et al.
HEPATOLOGY (2014)
Poster Session 4: HCV: Health Economics and Cost Effectiveness
HEPATOLOGY (2014)
Poster Session 4: Hepatitis C: New Agents (Not Approved)
HEPATOLOGY (2014)
All-Oral Combination of Ledipasvir, Vedroprevir, Tegobuvir, and Ribavirin in Treatment-Naive Patients With Genotype 1 HCV Infection
David L. Wyles et al.
HEPATOLOGY (2014)
Lack of a Clinically Important Pharmacokinetic Interaction Between Sofosbuvir or Ledipasvir and Hormonal Oral Contraceptives Norgestimate/Ethinyl Estradiol in HCV-Uninfected Female Subjects
P. German et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
RETREATMENT OF RELAPSERS TO SOFOSBUVIR/RIBAVIRIN WITH SOFOSBUVIR/LEDIPASVIR: COMPLETE AND RAPID VIROLOGIC SUPPRESSION BY WEEK 4
A. Osinusi et al.
JOURNAL OF HEPATOLOGY (2014)
SOFOSBUVIR/LEDIPASVIR FIXED DOSE COMBINATION IS SAFE AND EFFECTIVE IN DIFFICULT-TO-TREAT POPULATIONS INCLUDING GENOTYPE-3 PATIENTS, DECOMPENSATED GENOTYPE-1 PATIENTS, AND GENOTYPE-1 PATIENTS WITH PRIOR SOFOSBUVIR TREATMENT EXPERIENCE
E. J. Gane et al.
JOURNAL OF HEPATOLOGY (2014)
USE OF SOFOSBUVIR/LEDIPASVIR FIXED DOSE COMBINATION FOR TREATMENT OF HCV GENOTYPE-1 IN PATIENTS COINFECTED WITH HIV
A. Osinusi et al.
JOURNAL OF HEPATOLOGY (2014)
Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection
John O. Link et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Discovery and Development of Hepatitis C Virus NS5A Replication Complex Inhibitors
Makonen Belema et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
Eric Lawitz et al.
LANCET (2014)
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Kris V. Kowdley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885
Kelly A. Wong et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Earlier Sustained Virologic Response End Points for Regulatory Approval and Dose Selection of Hepatitis C Therapies
Jianmeng Chen et al.
GASTROENTEROLOGY (2013)
A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C
Eric J. Lawitz et al.
JOURNAL OF HEPATOLOGY (2012)
分享论文
